Can we accurately capture disease activity in pregnant patients with AS? Dr. Aurelie Najm ( @AurelieRheumo) discusses Abstract 0374. #ACR22 https://t.co/oafV1BP91X https://t.co/wMelZm5iOj

Treatment Persistence and Switching Patterns of an Adalimumab Biosimilar Dr. Julian Segan ( @JulianSegan) discusses Abstract 1425 at #ACR22 Abstract 1425: Treatment Persistence and Switching Patterns of AMGEVITA® in German Patients with RD https://t.co/MpNnrqYxGJ https://t.co/Sfi1kxOXLX

Fat and bone are never alone: osteoporotic fracture in RA Dr. David Liew discusses Abstract 889 at #ACR22. Abstract 889: Serum Adipokines Predict Incident Osteoporotic Fracture in Patients with Rheumatoid Arthritis https://t.co/4IrdQBq1z2 https://t.co/2HySVG1SGY

Topic Podcasts #ACR22 - SpA Part3 -Opioids and Health Care Utilization in PsA and AS -Reproductive health in a post-Roe world -SpA: Novel Therapies, Diagnostic Dilemmas and Depression -Tapering TNFi in nonradiographic AxSpA and more https://t.co/hXPlQaxPWs https://t.co/2SRYS6EOr7

How Underweight Women Can Reduce Hip Fracture Risk https://t.co/Czf3YJbD2r https://t.co/xKaZPTTOcS

Tyk2 Inhibition Effective in SLE Deucravacitinib, an oral, selective TYK2 inhibitor, has demonstrated efficacy in a phase II trial active systemic lupus erythematosus (SLE) patients. https://t.co/cpbDnkfUIS https://t.co/xct8dACBAY

RCT data on BTK inhibitor evobrutinib shows it to be well tolerated. Ph 2 RCT data on 1083 pts (RA, MS, SLE) Rx w/ evobrutinib(861) or placebo(271) for ~ 6 mos. No diff in TEAEs or EAIR , 2 deaths (SLE), SIE 2-3/100PY https://t.co/4HOTKuCAUi https://t.co/u7KSD6RN4q

Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After adjustments, wt-based dosing of HCQ not assoc w/ cardiac events(sHR 0.62; 0.41,0.92) & may decrease risk in non-smokers https://t.co/ufYcnuMI2r https://t.co/cOPIUpwpHf

JAMA - Update/Review of Hemochromatosis Dx and Rx. - 5 gene defects in hepcidin. 95% HFE & the C282Y variant - 90%are asymptomatic - Suspicion w/ arthralgias, LFTs, hepatomegaly, cardiomyopathy, 1st degr relative - Untreated, 9% risk of cirrhosis https://t.co/nuq8Ioralk https://t.co/djwlVsIk3b

#ACR22 - SpA Part2 -Comorbidities in Ankylosing Spondylitis -Early Diagnosis of AxSpA -Fertility issues in SpA -Gender in AxSpa -Inadequate Dosing of HCQ Leads to Hospitalizations in SLE -JAK inhibitors in RD -Opioid use in PsA and SpA https://t.co/1xJzSmekR2 https://t.co/kxpLGi8Ky4

#ACR22- SpA Part1 -AI Future of Sacroiliitis Assessment AI in Detecting Sacroiliitis -AxSpA: gender differences -Can we alter neonatal gut microbiome to prevent SpA? -Comorbidities in AxSpA -Do Disease Activity Measures Really Capture AS in Women? https://t.co/sFIZz7pKSF https://t.co/CAh5TZ4FEX

PreRA to Treat or Not! Dr. Janet Pope ( @Janetbirdope ) weighs in. #ACR22 https://t.co/778jWLizeW https://t.co/ZHIQTuYyyg